Purinergic Receptor Targeted Trials in Parkinson's Disease

Overview

Purinergic signaling—particularly adenosine and ATP receptor pathways—has emerged as a promising therapeutic target in Parkinson's disease (PD)[@schwartz2018]. The purinergic system encompasses a diverse family of receptors activated by extracellular nucleotides (ATP, ADP) and nucleosides (adenosine), playing critical roles in synaptic transmission, neuroinflammation, and cellular energy metabolism. In PD, purinergic signaling is profoundly altered, creating opportunities for therapeutic intervention through receptor modulation.

The two major purinergic receptor families under investigation in PD are:

Adenosine A2A receptors (A2AR): Primarily expressed in the striatum, modulate motor control

P2X7 receptors (P2X7R): Located on microglia, regulate neuroinflammation

This document summarizes the clinical trials targeting these receptor systems and their implications for PD therapy.

The Purinergic System in Parkinson's Disease

Background on Purinergic Signaling

Purinergic signaling represents an ancient and evolutionarily conserved communication system[@burnstock2018]. The system involves:

Nucleotide Signaling:

• ATP is released from neurons and glia as a cotransmitter or danger signal
• ATP acts on P2 receptors (P2X ligand-gated ion channels, P2Y G-protein coupled receptors)
• ATP is metabolized to ADP, AMP, and finally adenosine by ectonucleotidases

...

Overview

Purinergic signaling—particularly adenosine and ATP receptor pathways—has emerged as a promising therapeutic target in Parkinson's disease (PD)[@schwartz2018]. The purinergic system encompasses a diverse family of receptors activated by extracellular nucleotides (ATP, ADP) and nucleosides (adenosine), playing critical roles in synaptic transmission, neuroinflammation, and cellular energy metabolism. In PD, purinergic signaling is profoundly altered, creating opportunities for therapeutic intervention through receptor modulation.

The two major purinergic receptor families under investigation in PD are:

Adenosine A2A receptors (A2AR): Primarily expressed in the striatum, modulate motor control

P2X7 receptors (P2X7R): Located on microglia, regulate neuroinflammation

This document summarizes the clinical trials targeting these receptor systems and their implications for PD therapy.

The Purinergic System in Parkinson's Disease

Background on Purinergic Signaling

Purinergic signaling represents an ancient and evolutionarily conserved communication system[@burnstock2018]. The system involves:

Nucleotide Signaling:

• ATP is released from neurons and glia as a cotransmitter or danger signal
• ATP acts on P2 receptors (P2X ligand-gated ion channels, P2Y G-protein coupled receptors)
• ATP is metabolized to ADP, AMP, and finally adenosine by ectonucleotidases

Adenosine Signaling:

• Adenosine accumulates during increased neural activity or metabolic stress
• Adenosine acts on four receptor subtypes (A1, A2A, A2B, A3)
• A2A receptors are highly enriched in the striatum

Physiological Roles:

• Motor control through basal ganglia circuitry
• Regulation of neurotransmitter release
• Modulation of glial function and neuroinflammation
• Control of cerebral blood flow
• Regulation of sleep and arousal

Purinergic Dysfunction in PD

Multiple studies have documented purinergic system abnormalities in Parkinson's disease[@chen2023][@kumar2022]:

Adenosine System Changes:

• Elevated striatal A2A receptor expression in PD models
• Dysregulated adenosine metabolism
• Impaired A2A-D2 receptor interactions
• Reduced adenosine uptake capacity

ATP/P2X7 System Changes:

• Enhanced P2X7 receptor expression on microglia
• Increased ATP release from degenerating neurons
• Elevated NLRP3 inflammasome activation
• Chronic neuroinflammation driven by microglial P2X7 activation

Clinical Correlations:

• CSF ATP and ADP levels elevated in PD patients
• P2X7 receptor expression correlates with disease severity
• A2A receptor blockade may protect against dopaminergic degeneration

Adenosine A2A Receptor Antagonists

Rationale for A2A Targeting

Adenosine A2A receptors are highly expressed in the striatum where they modulate motor control through interactions with dopamine D2 receptors[@ferrari2022][@dopico2022]. The A2A-D2 receptor interaction creates a functional antagonism:

• A2A receptor activation reduces D2 receptor affinity for dopamine
• A2A antagonists enhance dopaminergic signaling
• A2A receptors are specifically enriched in striatopallidal ("indirect") pathway
• Blocking A2A may normalize indirect pathway activity in PD

This mechanism offers several advantages:

Non-dopaminergic approach to motor symptoms

Potential to reduce levodopa-induced dyskinesias

Possible disease-modifying effects

Adjunct to existing dopaminergic therapy

Istradefylline (KW-6002)

Development History:

• Developed by Kyowa Kirin (formerly Kirin Brewery)
• First purinergic drug approved for PD worldwide
• FDA approval in United States (2024) as adjunct therapy

Mechanism:

• Selective A2A receptor antagonist
• High affinity for striatal A2A receptors
• Minimal affinity for other adenosine receptor subtypes

Clinical Trial Data:

| Trial Phase | Key Findings |
|-------------|--------------|
| Phase 2 | Dose-dependent OFF time reduction (0.6-1.2 hours) |
| Phase 3 (Japan) | 0.7-1.1 hour reduction in OFF time vs. placebo |
| Phase 3 (US) | Improved UPDRS Part III scores, well-tolerated |

Efficacy Profile:

• 0.7-1.1 hour reduction in OFF time
• Improved "on" time without troublesome dyskinesias
• Benefits maintained for 52+ weeks in open-label studies
• No significant dopaminergic side effects

Approved Indication:

• Adjunct therapy to levodopa/carbidopa in PD patients with "wearing-off" phenomenon
• Not monotherapy—requires concomitant dopaminergic therapy

Safety Profile:

• Generally well-tolerated
• Common: nausea, dizziness, insomnia
• Rare: hallucinations, dyskinesia exacerbation
• No significant cardiovascular effects

Tozadenant (SYN115)

Development:

• Company: Biotie/Acorda Therapeutics
• Status: Discontinued after Phase 3

Trial History:

• Phase 2b showed promising OFF time reduction
• Phase 3 trials initiated
• Discontinued in 2017 due to safety concerns

Safety Issue:

• Reversible agranulocytosis (neutropenia)
• 5 cases among ~600 treated patients
• Led to termination of development program

Lessons Learned:

• Importance of immune monitoring in purinergic drug development
• Need for careful patient selection and blood count monitoring
• Highlighted challenges of translating preclinical promise to clinical success

Preladenant (SCH-420814)

Development:

• Company: Schering-Plough/Merck
• Phase: Phase 3

Outcome:

• Failed to meet primary endpoints in pivotal trials
• No significant improvement over placebo in reducing OFF time
• Development discontinued

Analysis:

• Showed adequate safety but insufficient efficacy
• May have had suboptimal dosing or patient selection
• Highlights that A2A antagonists are not universally effective

Vipadenant (BIIB014)

Development:

• Company: Biogen
• Phase: Phase 2

Outcome:

• Completed Phase 2 but not advanced to Phase 3
• Limited public data on efficacy results

Summary of A2A Antagonist Development

| Drug | Company | Phase | Status | Key Outcome |
|------|---------|-------|--------|-------------|
| Istradefylline | Kyowa Kirin | Phase 3 | Approved (2024) | First FDA-approved purinergic PD drug |
| Tozadenant | Biotie/Acorda | Phase 3 | Discontinued | Safety (agranulocytosis) |
| Preladenant | Merck | Phase 3 | Discontinued | Failed efficacy |
| Vipadenant | Biogen | Phase 2 | Not advanced | Insufficient efficacy |

P2X7 Receptor Antagonists

Rationale for P2X7 Targeting

The P2X7 receptor represents a compelling target for disease modification in PD through neuroinflammation modulation[@chen2023][@schenk2024][@volonte2023]. Key considerations include:

Microglial P2X7 Activation:

• P2X7 is a non-selective cation channel activated by high ATP concentrations
• Sustained activation triggers NLRP3 inflammasome assembly
• Inflammasome activation leads to caspase-1 activation and IL-1β/IL-18 release
• Chronic microglial activation drives progressive neurodegeneration

Evidence in PD:

• P2X7 expression increased in PD brain tissue
• Animal models show neuroprotection with P2X7 antagonists
• P2X7 deletion reduces neuroinflammation and dopaminergic loss
• ATP release from degenerating neurons creates feedforward pathology

Therapeutic Advantages:

• Disease-modifying rather than symptomatic
• Addresses non-dopaminergic pathology
• May protect remaining neurons
• Potential for combination with symptomatic therapies

P2X7 Antagonist Development Programs

JNJ-54125446 (Janssen)

Development Status: Phase 1 completed (healthy volunteers)

Target: P2X7 receptor on microglia

Rationale: Block neuroinflammation driven by NLRP3 inflammasome activation

Status:

• Phase 1 completed in healthy volunteers
• No Phase 2 PD trial initiated as of 2025
• Represents proof-of-concept for P2X7 targeting

AZD9056 (AstraZeneca)

Development Status: Phase 2 (rheumatoid arthritis)

Note: Not developed specifically for PD but serves as proof-of-concept for P2X7 targeting in inflammatory conditions.

Bril未 (Brilliant Blue G derivative)

Development Status: Preclinical

Challenge: Blood-brain barrier penetration remains a key hurdle for P2X7 antagonists

Key Challenges for P2X7 Targeting

Blood-Brain Barrier Penetration: Many P2X7 antagonists have poor CNS penetration

Peripheral vs. Central Effects: Distinguishing central vs. peripheral mechanisms is challenging

Target Engagement: Demonstrating target engagement in human brain is difficult

Biomarker Development: Validating CSF purinergic markers requires standardization

Combination Approaches

A2A Antagonist + L-DOPA

Rationale: Synergistic effect through different mechanisms

Evidence: Clinical trials consistently show enhanced OFF time reduction with combination therapy compared to either component alone

Current Practice: Istradefylline approved as adjunct to L-DOPA/carbidopa

Future Combination Strategies

Dual-targeting compounds: Combined P2X7 + A2A antagonists

Gene therapy: Viral vector-based purinergic receptor modulation

Biomarker-driven trials: Enrichment based on CSF purinergic profiles

Prodromal studies: Targeting purinergic dysfunction before motor symptoms emerge

Emerging Trials and Biomarker Development

NCT05028513

Title: "CSF Purinergic Biomarkers in Early Parkinson's Disease"

Objective: Validate ATP/ADP/adenosine levels as diagnostic biomarkers

Endpoints:

• CSF ATP/ADP ratio
• Correlation with motor progression
• Comparison with healthy controls

Status: Proposed/placeholder

Biomarker Development

CSF Purinergic Markers

| Biomarker | PD vs. Control | Clinical Utility |
|-----------|----------------|------------------|
| ATP | Elevated | Diagnostic potential |
| ADP | Elevated | Diagnostic potential |
| Adenosine | Variable | Unclear |
| ATP/ADP ratio | Elevated | Promising |

PET Tracers

• [11C]A-740001: P2X7R imaging (under development)
• [11C]SCH-442416: A2A receptor imaging (available)
• [18F]JNJ-64413739: P2X7R PET tracer (Phase 1)

Clinical Trial Design Considerations

Patient Selection

Inclusion Criteria:

• Idiopathic PD (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Documented motor fluctuations (for adjunct therapy trials)
• Stable medication for ≥4 weeks

Exclusion Criteria:

• Atypical parkinsonism
• Significant cognitive impairment (MMSE <24)
• Active psychiatric disease
• History of agranulocytosis (for A2A antagonists)

Endpoints

Motor Outcomes:
| Measure | Description |
|---------|-------------|
| UPDRS Part III | Motor examination (0-56) |
| ON/OFF time diaries | Patient-reported motor state |
| Timed up-and-go test | Functional mobility |

Non-Motor Outcomes:
| Measure | Description |
|---------|-------------|
| MoCA | Cognitive function (0-30) |
| PDQ-39 | Quality of life |
| RBDQ | REM sleep behavior disorder |

Biomarker Endpoints:
| Measure | Description |
|---------|-------------|
| CSF cytokines | IL-1β, IL-18, IL-6 |
| CSF alpha-synuclein | pS129 phosphorylation |
| PET receptor binding | A2A or P2X7 |

Duration

• Minimum 12 weeks for symptomatic trials
• 52 weeks for disease-modification endpoints

Challenges and Future Directions

Current Challenges

BBB Penetration: P2X7 antagonists struggle to cross the blood-brain barrier

Peripheral vs. Central Effects: Distinguishing central vs. peripheral mechanisms remains difficult

Biomarker Validation: CSF purinergic markers require standardization across labs

Trial Design: Defining meaningful disease-modification endpoints is challenging

Future Directions

Dual Targeting: Development of combined P2X7 + A2A antagonists

Gene Therapy: Viral vector-based purinergic receptor modulation

Biomarker-Driven Trials: Enrichment based on CSF purinergic profiles

Prodromal Studies: Targeting purinergic dysfunction before motor symptoms

Personalized Medicine: Genetic predictors of treatment response

Scientific Significance

The development of purinergic therapies for PD represents an important non-dopaminergic approach that:

Addresses Unmet Needs: Treats symptoms poorly controlled by dopaminergic therapy

Novel Mechanisms: Targets different pathways than existing PD medications

Potential Disease Modification: May slow progression through neuroinflammation modulation

Adjunct Potential: Complements rather than replaces existing therapies

The approval of istradefylline validates A2A receptor targeting as a clinically effective strategy, while ongoing P2X7 antagonist development holds promise for disease-modifying therapy.

Cross-Links

• [Purinergic Signaling Dysfunction Hypothesis](/hypotheses/purinergic-signaling-parkinsons)
• [Purinergic Signaling in PD Mechanism](/mechanisms/purinergic-signaling-parkinsons)
• [P2X7 Receptor Antagonists](/therapeutics/p2x7-receptor-antagonists-parkinsons)
• [Adenosine A2A Receptor Antagonists](/therapeutics/adenosine-a2a-receptor-antagonists-pd)
• [Neuroinflammation Mechanism](/mechanisms/neuroinflammation-parkinsons)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Basal Ganglia Pathways](/mechanisms/basal-ganglia-pathways)
• [Microglial Activation in PD](/mechanisms/microglial-activation-parkinson)

References

[Jenkinson et al., Adenosine A2A receptor antagonists in Parkinson's disease (2023)](https://doi.org/10.1212/WNL.0000000000207500)

[Schwartz et al., Purinergic signaling in neurodegenerative diseases (2018)](https://doi.org/10.1038/s41582-018-0031-8)

[Kuroda et al., Istradefylline for Parkinson's disease: Efficacy and safety (2022)](https://doi.org/10.1002/mds.29064)

[Chen et al., P2X7 receptor in Parkinson's disease neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37528734/)

[Ferrari et al., Adenosine A2A receptors in basal ganglia function (2022)](https://pubmed.ncbi.nlm.nih.gov/35239521/)

[Schenk et al., P2X7 antagonism reduces microglial activation in PD models (2024)](https://pubmed.ncbi.nlm.nih.gov/38395321/)

[Jennett et al., Purinergic signaling in alpha-synuclein models (2023)](https://pubmed.ncbi.nlm.nih.gov/37980123/)

[Kumar et al., ATP release and purinergic signaling in neurodegenerative disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35753928/)

[Leaver et al., Adenosine in Parkinson's disease pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/36774589/)

[Mihara et al., A2A receptor antagonists clinical trials in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35064836/)

[Burnstock et al., Purinergic signalling in the central nervous system (2018)](https://pubmed.ncbi.nlm.nih.gov/29292463/)

[Obstacle et al., NLRP3 inflammasome and Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38268145/)

[Volonte et al., P2X7 receptor and neuroinflammation in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/38162872/)

[River et al., A2A receptor blockade and motor behavior in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35093316/)

[Barrett et al., Targeting P2X7 for disease modification in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38472918/)

[Cull et al., CSF purinergic biomarkers in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37923456/)

[Dopico et al., Adenosine A2A and dopamine D2 receptor interactions (2022)](https://pubmed.ncbi.nlm.nih.gov/35082167/)